---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-025907"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:14:02.153553+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics reports $337M cash, $42M ATM proceeds, runway into late-2026

## Summary
- Cash, cash equivalents and marketable securities at Dec 31, 2023: $337M (unaudited).
- Net proceeds of $42M from at-the-market offering completed in January 2024.
- Company estimates sufficient cash to fund operations into late-2026.
- Figures are preliminary and subject to completion of financial closing procedures.

## SEC filing metadata
- accession: 0001193125-24-025907
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312524025907/0001193125-24-025907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312524025907/d694316d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-025907
- JSON: https://secwatch.observer/filing/0001193125-24-025907.json
- Plain text: https://secwatch.observer/filing/0001193125-24-025907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.